“Direct to Drug” screening as a precision medicine tool in multiple myeloma

Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation, and tran...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Cancer J
Autores principales: Bonolo de Campos, Cecilia, Meurice, Nathalie, Petit, Joachim L., Polito, Alysia N., Zhu, Yuan Xiao, Wang, Panwen, Bruins, Laura A., Wang, Xuewei, Lopez Armenta, Ilsel D., Darvish, Susie A., Ahmann, Greg J., Henderson, Kimberly J., Tian, Shulan, Kruse, Jonas J., Stewart, William M., Larsen, Jeremy T., Reeder, Craig B., Dingli, David, Kapoor, Prashant, Kumar, Shaji K., Fonseca, Rafael, Bergsagel, P. Leif, Braggio, Esteban, Stewart, A. Keith
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214452/
https://ncbi.nlm.nih.gov/pubmed/32393731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-0320-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares